Anti-Hypertensive Activity of Timolol Maleate Nanoparticle Loaded Transdermal Patch on Dexamethasone Induced Hypertensive Rats by Birendra Shrivastava et al.
 
Asian Pac. J. Health Sci., 2019; 6(2):145-151                                            e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Shrivastava et al               ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2019;6(2):139-145                                           145 
www.apjhs.com       
 
 
Document heading doi: 10.21276/apjhs.2019.6.2.21                                                                                            Research Article 
Anti-Hypertensive Activity of Timolol Maleate Nanoparticle Loaded Transdermal Patch 
on Dexamethasone Induced Hypertensive Rats 
Birendra Shrivastava1, Parveen Kumar1,2*, Madan Mohan Gupta1,3, Anil Kumar Sharma2 
1
School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India 
2 Shri Ram college of Pharmacy, Karnal, Haryana, India 
3 Laboratory of Pharmaceutical Formulation Design and Development, School of Pharmacy, Faculty of Medical 
Sciences, The University of The West Indies, Trinidad & Tobago, West Indies 
 
Received: 15-03-2019 / Revised: 20-4-2019 / Accepted: 25-04-2019 
 
Abstract 
 
The rationale of the current work was to evaluate antihypertensive activity ofTimolol maleate nanoparticles loaded 
transdermal patch. Nanoparticles loaded transdermal patch of timolol maleate was prepared using Compritol 888, 
Lutrol F68, tween 80 etc. The formulated patches were subjected to skin irritation study and in–vivo 
antihypertensive activity. Hypertension was induced by dexamethasone in experimental rats. No any marked skin 
irritation observed before and after applying the patch. Both systolic and diastolic blood pressure in experimental 
animals was reduced significantly after 7 days treatment with Timolol maleate nanoparticles loaded transdermal 
patch. So, it was concluded that timolol maleate patch could be formulated into a matrix-type naoparticle loaded 
transdermal patch for the management of hypertension. Also, this study can be considered as a new report that 
focuses on the problem of the side-effects associated with the modern medicaments toward hypertension 
 
Keywords: Hypertension, Timolol maleate, Transdermal patches.
Introduction 
Hypertension is known to be one of the major risk 
factors for the occurrence of death from 
cardiovascular diseases. Although, there are 
involvement of various risk factors contributing to 
CVD death but hypertension is considered to be one 
of the important risk factors for all forms of 
cardiovascular and renal disease [1,2].According to 
World Health Organization-International Society of 
Hypertension (WHO/ISH) Guidelines for the 
Management of Hypertension, hypertension is 
defined as a systolic blood pressure (SBP) of 140 mm 
Hg or greater and/or a diastolic blood pressure (DBP) 
of 90 mmHg or greater in subjects who are not taking 
antihypertensive medication.  
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In the epidemiological study, hypertension is 
commonly defined as in the same way i.e. SBP/DBP 
of 140 mm Hg or greater and/or 90 mmHg or greater 
measured on one visit. There are different factors like 
race/ethnicity, age, level of education, origin of birth, 
low family income, diabetes, obesity, disability status 
and insurance are the motives for the note worthy 
dissimilarities in the dominance of hypertension [3].  
According to Warren-Find low et al., (2011) [4] in 
hypertension condition can be prevented when one 
should take care of his or herself very well by 
managing healthy and good life style.  Bosworth et 
al., (2006) [5] believe that self-efficacy is especially 
important to hypertension self-care. It is very 
essential to manage and taking care of themselves to 
a changeable characteristic and, consequently, is 
open to intervention [6]. Now a day, the proper 
management and prevention of hypertension became 
the global health care challenge throughout the 
world. One of the best ways to manage the 
hypertension condition by following a healthy 
lifestyle and changing environment. Apart from 
maintaining healthy lifestyle body weight 
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management is also important. It is also suggested to 
reduce the intake of total fat and saturated fat[7].   
There are large number of drugs are presently 
available for the treatment of hypertension disease. 
These anti-hypertensive drugs are classified into 
different groups: 
1. Diuretics, where thiazide diuretics  
(hydrochlorothiazide, chlorothiazide, indapamide). 
2. Beta-blockers (e.g. atenolol, timolol, 
bisoprolol, metoprolol) 
3. Angiotensin converting enzyme inhibitors 
(e.g.  enalapril, lisinopril, perindopril) 
4. Angiotensin receptor blockers (e.g. 
telmisartan, valsartan, losartan) 
5. Calcium channel blockers (e.g. nifedipine, 
amlodipine, nicardipine) 
6. Alpha 1 Blockers (e.g. prazosin) 
7. Central alpha 2 agonists (e.g. methyldopa) 
8. Direct vasodilators (e.g. hydralazine, 
minoxidil).  
The above maintained drug groups are being largely 
tested in many clinical trials. Data and results of the 
clinical trial showed that drugs of above maintained 
groups are successfully and effectively reduce blood 
pressure and CVD events such as coronary heart 
diseases, strokes, and heart failure [8].  Still there is 
lots of adverse or side effects such as drug 
metabolism by first pass effect in the liver, poor 
patient compliance, or rejection of an invasive 
medication often hamper the success and efficacy of 
therapeutic treatment. To overcome these problems 
many drug carriers were developed but some carrier 
such as liposomes, niosomes, or micro emulsions has 
problem that they remain mostly confined to the skin 
surface and therefore do not transport drugs 
efficiently through the skin [9]. To overcome the 
problem of the stratum corneum barrier, various 
approaches can be adopted. These include 
augmentation of skin permeability using penetration 
enhancers, use of forces which are not dependent on 
concentration gradient (Iontophoresis, 
electroporation, phonophoresis, microneedles, jet 
injectors, etc.,) and more recently the drug carrier 
systems like vesicles[10]. Drug delivery systems 
using vesicular carriers such as nanoparticles loaded 
transdermal patch have soft, flexible, self-regulating 
and self-optimising vesicular characteristics. 
Flexibility of transdermal patches membrane is 
achieved by mixing suitable surface-active 
components in the proper ratios[11]. These properties 
allow them to penetrate easily into deeper layers of 
the skin and circulation. 
 
Nanoparticles Loaded Transdermal Patch 
Nanotechnology is broadly defined as the study and 
use of structures in range between 1 to 1000 
nanometers in size. Nanotech-enabled products 
discovery and its applicability in practically 
everything we touch on a day-to-day basis, such as 
medicine, pharmaceuticals, chemicals, and 
information technology[12]. In particular, the 
pharmaceutical industry has been energized with 
breakthroughs in nano-engineering, especially in 
the fields of drug delivery and formulation 
development. Over the last few periods, there has 
been an outburst of research at both academic and 
industrial levels - pertaining to nanoformulations: 
nanoparticles, liposomes, [13], nano-emulsions 
[14]and dendrimers [15]. 
Transdermal patches are dosageforms that are 
placed on the skin to deliver a therapeutically 
effective amountofmedication or drug to the skin 
and into the systemic circulation. Several system 
designs have been used in development and 
formulationof transdermal patches.  
Drug permeation through skin and permeation 
enhancement methods 
The skin is the biggest organ of the body, 
representing over 10% of weight. Broad 
investigations have demonstrated that the skin is 
more unpredictable than simply a boundary and this 
becomes apparent when agents are applied to the skin 
either intentionally or incidentally. The degree of 
assimilation through the epidermis, dermis and 
systemically becomes important when we consider 
that medicament is applied to the skin (figure 1). A 
few speculations have been proposed for drug entry 
through the stratum corneum into the viable 
epidermis and dermis, including the ''bricks and 
mortar'' hypothesis, representing to keratinocytes held 
together by a lipid bilayer. In any case, contrasts in 
skin thickness, density of skin appendages (hair 
follicles and organs), vascularity and metabolic 
enzymes imply that diverse areas of skin in a similar 
individual presentation distinctive pharmacokinetics 
of percutaneous drug penetration.  
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Figure 1: Different approaches for skin permeation enhancement 
Material and methods 
Chemicals and reagents used 
Timolol Maleate (TM) was generously gifted by 
Gangwal Pharmaceuticals, Mumbai, India. Tween 20 
and PEG 400 was purchased from SD Fine 
Chemicals, Compritol 888 ATO from Gettefosse 
(India) Pvt. Ltd; Mumbai, Lutrol F68 from BASF, 
India. HPMCK 100M was gifted by Colorcon Asia 
Pvt. Ltd; Goa, Analytical grades of orthophosphoric 
acid and Nylon membrane filters (0.45µm) were 
purchased from Fisher Scientific (Mumbai, India). 
All aqueous solutions were prepared using Milli 
Q/Elix water (Millipore, Moscheim Cedex, France). 
All other chemicals used were of analytical grade. 
Formation of transdermal patch 
In order to prepare Solid Lipid Nanoparticles 
(SLN) of TM, various ingredientsviz. Compritol 
888, Lutrol F68, tween 80 etc. were selected on the 
basis of literature reports.[16]. These ingredients 
were tried in different concentration to develop 
suitable SLN’s of TM. 
Solid Lipid Nanoparticlespreparations 
To purified water Lutrol F68 and tween 80 are added 
under stirring to get a clear solution and the 
temperature maintained at 85-90ºC (5% overages of 
purified water taken to compensate loss on heating). 
Compritol 888 ATO is heated to melt to this Timolol 
maleate is added under stirring to get a clear solution. 
Above mixture added and mixed using ultratrax 
stirrer at 13000 rpm for 15 min by maintaining the 
temp at 85-90ºC. After homogenization the 
dispersion is kept aside to come to room temperature. 
[16] 
Preparation of SLNs Transdermal Patches 
Transdermal patches containing Timolol Maleate 
were prepared by solvent casting technique 
employing mercury as substrate. Different 
formulations were formulated using different grades 
of HPMC i.e. HPMC K100M, HPMC 50 cps and 
ethyl acetate, different percentage of glycerine and 
100mg of optimized nanoparticles. The prepared 
solution was poured into glass petri dishes of 25 cm2 
area and dried at room temperature [16]. After 12 h, 
the patches were cut in 5 cm2 area and packed in 
aluminium foil. 
Experimental animals 
Forty-five Wistar albino rats in adult size of either 
sex in weight ranging from 150-200 g were used for 
the study and were kept in groups and each group 
consists of nine animals. Animal obtained from the 
Institute of Biomedical and industrial research, 
Jaipur. Under standard environmental conditions, the 
animals were allowed to acclimatize. The animals 
were kept in the animal house. Each group was kept 
in clean poly-acrylic cages lined with husk, renewed 
every 48 h. It was maintained for 12 hrs. day and 
light cycles at an average of ambient temperature 
of25± 2o C and 60±10% relative humidity (RH). All 
the animals had free access to standard pellet diet and 
water during the exposure of treatment. The 
experiment was carried out according to the 
guidelines of the committee for the purpose of 
control and supervision of experiments on Animal 
(CPCSEA). The experimental protocol was approved 
by the Institutional Animal Ethics Committee, 
Institute of Biomedical and industrial research, Jaipur 
wide protocol approval number IAEC/2018-07/04. 
Experimental design 
The animals were divided in to 5 main groups, each 
group contain 9 animals. Group I received normal 
saline, Group II received dexamethasone 
subcutaneous injection plus normal saline (35 μg/ 
rat)for 7 days, Group III received nicorandil (6mg/kg, 
oral), Group IV received transdermal patch with 
penetration enhancer of timolol maleate, Group V 
received solid lipid nanoparticle loaded transdermal 
patch of timolol maleate[17, 18]. 
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Skin Irritation Study 
The selected formulation was tested for its potential 
to cause skin irritation/sensitization in rats. Skin 
irritation studies designed to detect irritation under 
conditions of maximal stress and during the 
assessment of transdermal drug products. Study 
performed on Wister rats for 7 days. Skin irritation 
study performed as the group assigned. Patches are 
applied on the backside of hairless skin of rats for 23 
± 1 hr up to 14 days to the same skin site. After 24 
hrs if any type of irritation found then patch should 
be applied on other site. Each day skin was examined 
for any type of major and minor skin reactions as 
mention below scale of 0 to 7 numbers, as per the 
literature. 
Table:1The ranking of irritation in animals 
Ranking and Criteria 
0- No evidence of irritation 
1- Minimal erythema, barely perceptible 
2- Definite erythema, readily visible; minimal edema or minimal popular response 
3- Erythema and papules 
4- Definite edemal 
5- Erythema, edema, and papules 
6- Vesicular eruption 
7- Strong reaction spreading beyond test site 
Evaluation of in-vivo antihypertensive activity 
In the experimental rats, hypertension was induced 
by subcutaneous injection of dexamethasone 
(10 μg/kg/d) in the evening. Each rat was educated 
and familiarized to the restrainer and transducer, for 
about 15 mins before the experiment. The rat was 
nonaggressive in a low-stress environment and 
allowed to enter the holder freely at least 10–15 min 
prior to obtaining BP measurements[19]. The 
animal's nose was made to protrude through the front 
of the nose cone permitting for relaxed breathing and 
the tail of the animal was fully prolonged to exit 
through the rear hatch opening of the holder. The rat 
was warmed but not heated using restrainer, the room 
temperature was maintained about 32–35.4°C, reduce 
stress and the blood flow to the tail was enhanced to 
acquire a BP signal[20](Vijayan et. al., 2011). The 
rat never had its head bent sideways or its body 
compressed against the back hatch. The animal's 
temperature was monitored throughout the 
experiment as the procedure suggested by Vijayan et. 
al., 2011[20]. 
Estimation of systolic and Diastolic blood pressure 
Systolic blood pressure (SBP) measurements were 
recorded weekly by the same investigator, between 
10-12 AM, using the integrated BIOPAC instrument 
(Non-Invasive Blood Pressure 200A system). The 
basic software setup is done, and IR sensors are 
calibrated prior to starting the measurement. An IR 
sensor is then connected to the tail of the animal 
inside the restrainer. After the required setup and 
calibration of IR sensors, SBP was recorded. 
Statistical analysis 
Statistical analysis was carried out by two-way 
analysis of variance followed by Bonferroni post-
tests. All values were expressed as mean ± standard 
error of the mean. All groups were compared with 
hypertensive control animals. A p value of <0.05 was 
considered to be statistically significant. 
Results and discussion 
Skin Irritation Study 
The skin irritation test of the transdermal patch 
showed a skin irritation score (erythema and edema) 
of less than 2 (Table 1). According to Trushet.al.[21], 
compounds producing scores of 2 or less are 
considered negative (Table 2) (no skin irritation). 
Table 2: Skin irritation Draize score of transdermal patches 
Draize score  Erythema (before) Erythema (after) 
1 0 1 
2 0 1 
3 0 0 
4 0 0 
5 0 1 
6 0 1 
Average 0 0.66±16  
(n=6±SD) 
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Evaluation of in-vivo antihypertensive activity 
Among diverse models available, for the existent 
study, the dietary induction of hypertension in Wistar 
rats was employed using dexamethasone according to 
methods described by Jena et al[22]. The animal's 
temperature was monitored throughout the 
experimentMalkoff, 2005[23]. After 14 days 
treatment SLN patch showed maximum significant 
attenuation in Blood pressure as compared to 
hypertensive control animals. 
Table:2 Measured Systolic blood pressure of different groups of rats 
Sr. No.  Group  0th day 7th day 14th day 
1 Control  110±2.11 109±3.25 105±3.77 
2 Hypertensive control  107.2±2.25 123.5±3.11 132.5±2.24 
3 Standard  108.5±1.75 113.5±2.42* 110.6±3.06* 
4 Test I Patch  111.6±2.46 118.4±2.25 117.5±3.60* 
5 Test II SLN Patch 109.5±2.35 114.2±3.15 112.6±2.60* 
 
Table: 3 Measured Diastolic blood pressure of different groups of rats 
Sr. No.  Group  0th day 7th day 14th day 
1 Control  76.2±2.50 77.5±2.85 78.6±2.30 
2 Disease control  78.2±3.15 88.8±3.47 92.2±3.25 
3 Standard  77.6±2.85 81.3±2.11 79.2±3.10* 
4 Test I Patch  75.8±2.01 85.2±2.50 83.4±2.78* 
5 Test II SLN Patch 77.2±3.22 84.3±3.10 81.5±2.15* 
*Significant P‹0.05 as compared to disease control  
 
Figure 2: Graphs showing Systolic blood pressure of rats 
 
 Figure 3: Graphs showing Diastolic blood pressure of rats 
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Results revealed that as hypertension induced rats 
along with prepared nano-particle formulation of TM is 
a non-skin irritant. When rats were treated with SLNs 
along it produce irritation with minimal erythema after 
10 days and definite erythema, readily visible edema 
was produced after 12 days. Compared with this both 
the placebo and optimized batch was not show any type 
of irritation up to 10 days after that there was little 
erythema found with light redness at the site of 
application. These results of in-vivo skin irritation 
study suggested that optimized batch TM19 does not 
show any type of major irritation on rat skin up to 14 
days and it was safely used up to 24 hrs., photographs 
of optimized batch TM19 after in-vivo skin irritation 
study shown in Figure. 4.  
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
Figure 4: Showing no any redness or spot before and after patch application 
Conclusion 
In this present study, Transdermal patch evaluated for 
anti-hypertensive study and a skin irritation study. No 
any marked skin irritation observed before and after 
applying the patch.Henceforward, this study can be 
considered as a new report that focuses on the problem 
of the side-effects associated with the modern 
medicaments toward hypertension.  
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